Ensysce Biosciences, Quotient Partner To Work On Novel Opioid To Prevent Abuse and Overdose

Ensysce Biosciences Inc ENSC and Quotient Sciences, a drug development and manufacturing accelerator, announced a partnership to support the development and clinical testing of PF614-MPAR.
PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain designed to prevent abuse and overdose.
Quotient Sciences is currently using its integrated Translational Pharmaceutics platform to identify a PF614-MPAR formulation that allows conversion into oxycodone within the prescribed dose range but reduces conversion to oxycodone at higher than prescribed dose levels in an overdose scenario.
The formulation will be an optimized composition that balances dose and release rate.
The candidate formulations being tested in the clinic have been selected from emerging clinical data to achieve the desired exposure profile, allowing formulation optimization in humans rather than preclinical species.
Price Action: ENSC shares are down 4.90% at $0.40 on the last check Thursday.